On June 30, 2017 AskAt Inc. reported that AskAt received a notice of allowance dated June 30, 2017 from Office of the Controller General of Patent, Designs & Trade Marks in connection with the Application No. 817/DELNP/2006, a substance patent for its EP4 antagonist(AAT-007) (Press release, AskAt, JUN 30, 2017, View Source [SID1234535062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!